NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed)
ID: 343474Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), is inviting proposals for investigator-initiated Program Project (P01) applications focused on critical research areas related to infectious diseases and immune-mediated conditions. Applicants are required to submit proposals that include at least two related research projects sharing a common theme, along with an administrative core, while clinical trials are not permitted under this funding opportunity. This initiative aims to enhance collaborative research efforts to address significant health challenges, including the biology of infectious microbes and the development of vaccines and therapeutics. Interested applicants can find more information and submission guidelines at the provided link, with the next application deadlines set for January 11 and June 8, 2023, and a final close date of September 7, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    Files
    Title
    Posted
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), invites proposals for investigator-initiated Program Project (P01) applications focused on critical research areas. The funding aims to address topics like infectious disease mechanisms, immune system interactions, and translational research for therapeutics and diagnostics. Each application must include at least two related research projects with a shared central theme, along with an administrative core. Clinical trials are prohibited under this funding announcement. Key application deadlines include January 11 and June 8 for non-AIDS projects in 2023, with multiple review dates extending into 2026. The application process requires compliance with detailed submission guidelines, including registrations with Grants.gov, SAM, and eRA Commons. NIH emphasizes the importance of integrated research efforts to achieve significant scientific advancements compared to isolated studies. Reviews will consider the overall impact, significance, innovation, and coordination of projects. The announcement reflects NIH's ongoing commitment to enhance research capabilities in infectious and immune-mediated diseases, ensuring a collaborative and multidisciplinary approach to health research.
    Similar Opportunities
    NIA Program Project Applications (P01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIA Program Project Grants (P01 Clinical Trial Optional), aimed at advancing research in aging-related scientific areas. Applicants must propose at least three interrelated research projects centered around a common theme, along with an administrative core to manage the initiative, addressing topics such as genetics, biology, and Alzheimer’s disease. This funding opportunity is crucial for fostering collaborative research efforts among established scientists and early-career researchers, ultimately contributing to the understanding and improvement of public health concerning aging. Interested organizations must submit their applications by September 7, 2025, and can find additional details and requirements at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), is offering a funding opportunity for investigator-initiated Resource-Related Research Projects (R24), specifically excluding clinical trials. This initiative aims to enhance existing high-priority research by supporting resources that provide critical data, materials, tools, or services beneficial to the scientific community, particularly in areas related to immunology and infectious diseases. Eligible applicants include a diverse range of institutions, such as higher education and nonprofit organizations, with proposals due by January 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-23-065.html.
    National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health, through the National Cancer Institute (NCI), invites applications for Program Project grants (P01) aimed at fostering collaborative, multidisciplinary cancer research for the years 2023, 2024, and 2025. Applicants must propose at least three interrelated research projects and an Administrative Core, all centered around a common theme within the expansive field of cancer research, which includes areas such as cancer biology, prevention, diagnosis, treatment, and control. This funding opportunity is crucial for advancing cancer research and enhancing the effectiveness of collaborative efforts, with applications due by May 7, 2026. Interested parties can find more information and application guidelines at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    NIDA Program Project Grant Applications (P01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is inviting applications for Program Project Grants (P01 Clinical Trial Optional) aimed at fostering collaborative, multidisciplinary research on substance use disorders. Applicants must propose a minimum of three interrelated research projects that demonstrate scientific and administrative synergy under a unifying theme, addressing critical issues such as neuroscience, genetics, behavior, prevention, treatment, and health services related to substance use. This funding opportunity emphasizes inclusivity, requiring a Plan for Enhancing Diverse Perspectives (PEDP) and encouraging participation from underrepresented groups, with a maximum project duration of five years. Interested applicants can find more information and submit inquiries via grantsinfo@nih.gov, with applications due by January 7, 2026.
    Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)" to stimulate research aligned with the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This initiative aims to support research on HIV-related comorbidities, gastrointestinal diseases, and metabolic disorders associated with HIV, encouraging applications from a diverse range of organizations, including higher education institutions and non-profits. With an estimated funding of $2 million for fiscal year 2025, the NIH plans to support 3 to 5 selected projects over a maximum project period of five years, with applications undergoing a rigorous peer review process. Interested applicants can find more information and submit their proposals through Grants.gov, with a submission deadline of January 7, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)" aimed at supporting research on infectious diseases in resource-constrained countries. This initiative encourages applications from organizations based in low- and lower-middle-income economies, as classified by the World Bank, and seeks innovative proposals addressing diseases such as HIV/AIDS, tuberculosis, and malaria, with a focus on enhancing local scientific capacity. The total funding available for fiscal year 2024 is approximately $1,360,000, with individual project budgets capped at $125,000 per year for a maximum of five years. Interested applicants can find more information and submission guidelines at the NIH website, with applications accepted until August 1, 2025.
    NINDS Program Project Grant (P01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Neurological Disorders and Stroke (NINDS), is offering the Program Project Grant (P01) to support innovative, collaborative research addressing significant scientific questions within its mission. This grant encourages multi-disciplinary projects that are interdependent, allowing for greater scientific advancements than individual efforts, and applications may include clinical trials, although those focused on intervention effectiveness should seek different funding opportunities. Eligible applicants include higher education institutions, nonprofits, and governmental entities, with funding of up to $1 million in direct costs per year available for a maximum project period of five years. Interested parties should consult with NINDS staff early in the proposal process, with the application submission period opening on April 25, 2024, and due by May 25, 2024; for further inquiries, contact grantsinfo@nih.gov.
    NHLBI Program Project Applications (P01 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), has announced a funding opportunity for Program Project (P01) grant applications aimed at advancing research in heart, lung, and blood diseases. Applicants are required to submit proposals that include a minimum of three interrelated research projects focused on a common biomedical theme, with the option to incorporate clinical trials. This initiative is designed to foster collaborative research efforts and encourage innovative scientific directions, particularly supporting projects led by Early Stage Investigators (ESIs). The maximum funding for awarded projects is capped at $1.515 million annually, or $1.765 million if an ESI-led project is included, with a project duration of up to five years. Interested applicants can find more information and submit their proposals electronically via Grants.gov, with a closing date for applications set for September 25, 2026. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Understanding Mechanisms and Outcomes of Trained Immunity (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Understanding Mechanisms and Outcomes of Trained Immunity" (FO No. PAR-24-112) aimed at enhancing research on innate immune memory. This initiative seeks to support studies that identify biomarkers of trained immunity, elucidate underlying molecular mechanisms, and assess the implications for immune system function, particularly in relation to vaccines, infections, and autoimmune or allergic diseases. The funding is crucial for advancing immunological research with significant public health implications, and applications are due by June 5, 2024, and October 5, 2024. Interested applicants can find more information and submit their proposals via Grants.gov, and for inquiries, they may contact NIH Grants Information at grantsinfo@nih.gov.
    Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)." This initiative aims to encourage research into the role of inflammasomes in the neuropathology associated with HIV infection and substance use disorders, particularly focusing on their impact on neurocognitive disorders and immune function. The program seeks to bridge knowledge gaps in treatment and research by exploring how inflammasome activation is influenced by HIV and substance use, with the goal of translating findings into clinical applications. A total funding amount of $2 million is available to support up to four grants, with a submission deadline of February 13, 2024. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.